To reduce the burden associated with stroke, investigations of efficacy of available treatments for patients with stroke such as intravenous injection of recombinant tissue plasminogen activator (rt-PA) are necessary.[7,8] Since the US Food and Drug Administration approval in 1996, intravenous thrombolysis (IVT) with rt-PA is the only effective and recognized method in the treatment of acute stroke. The gene discussed is PLAT; the disease is Stroke.